Menu Search
Equities

Guardion Health Sciences Inc

0QTA:STU

Guardion Health Sciences Inc

Actions
  • Price (EUR)8.30
  • Today's Change0.20 / 2.47%
  • Shares traded0.00
  • 1 Year change+40.68%
  • Beta--
Data delayed at least 15 minutes, as of May 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Guardion Health Sciences, Inc. is a clinical nutrition company. The Company offers a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients. The Company, through Activ Nutritional, LLC (Activ), owns the Viactiv line of supplements for bone health and other applications. The Viactiv line of supplements contains several flavored nutritional supplement products, but the milk chocolate and caramel flavored calcium chews constitute the main product category. It also sells Lumega-Z, its medical food product that has a formula designed to replenish and restore the macular protective pigment, simultaneously delivering critical and essential nutrients to the eye. The Company's GlaucoCetin is a dietary supplement in a capsule form designed specifically to provide nutrients to support mitochondrial function with additional antioxidants to help reduce oxidative stress.

  • Revenue in USD (TTM)12.06m
  • Net income in USD-5.12m
  • Incorporated2015
  • Employees9.00
  • Location
    Guardion Health Sciences Inc2925 Richmond Avenue, Suite 1200HOUSTON 77098United StatesUSA
  • Phone+0 (1800) 873-5141
  • Fax+1 (858) 630-5543
  • Websitehttps://www.guardionhealth.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.